Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H. Shibaki R, et al. Among authors: kitamura y. J Immunother Cancer. 2024 Feb 15;12(2):e007987. doi: 10.1136/jitc-2023-007987. J Immunother Cancer. 2024. PMID: 38360040 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: kitamura y. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K. Fujimoto D, et al. Among authors: kitamura y. Anticancer Res. 2018 Dec;38(12):6891-6895. doi: 10.21873/anticanres.13065. Anticancer Res. 2018. PMID: 30504406
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.
Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Ogura T, et al. Among authors: kitamura y. Respir Investig. 2019 Nov;57(6):512-533. doi: 10.1016/j.resinv.2019.06.001. Epub 2019 Aug 1. Respir Investig. 2019. PMID: 31377122 Review.
Standardized Classification of Lung Adenocarcinoma Subtypes and Improvement of Grading Assessment Through Deep Learning.
Lami K, Ota N, Yamaoka S, Bychkov A, Matsumoto K, Uegami W, Munkhdelger J, Seki K, Sukhbaatar O, Attanoos R, Berezowska S, Brcic L, Cavazza A, English JC, Fabro AT, Ishida K, Kashima Y, Kitamura Y, Larsen BT, Marchevsky AM, Miyazaki T, Morimoto S, Ozasa M, Roden AC, Schneider F, Smith ML, Tabata K, Takano AM, Tanaka T, Tsuchiya T, Nagayasu T, Sakanashi H, Fukuoka J. Lami K, et al. Among authors: kitamura y. Am J Pathol. 2023 Dec;193(12):2066-2079. doi: 10.1016/j.ajpath.2023.07.002. Epub 2023 Aug 5. Am J Pathol. 2023. PMID: 37544502
2,372 results